Awakn Life Sciences will be carrying out the first-ever study investigating the use of ketamine treatment for gambling addiction, using psychedelic-assisted psychotherapy.
A systematic review of medical research has shown that ketamine and esketamine show no adverse cognitive effects in treatment-resistant depression.
A team of researchers has identified novel mechanistic insights on how ketamine exerts an anti-depression effect, raising the hope of finding new treatment options for the...
Awakn Life Sciences has announced the opening of its second psychedelic therapy clinic that will be located in London.